A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer
- William J. Gradishar
- , Virginia Kaklamani
- , Tarini P. Sahoo
- , Dasappa Lokanatha
- , Vinod Raina
- , Shailesh Bondarde
- , Minish Jain
- , Sunhee Kwon Ro
- , Nathalie A. Lokker
- , Lee Schwartzberg
Producción científica: Article › revisión exhaustiva
86
El enlace se abre en una pestaña nueva
Citas
(Scopus)